08.08.25 -- STREAM Edition: Functional Antibody Screening With Abalone Bio's Richard Yu, Ph.D.

This presentation discusses the shift in pharmaceuticals from small-molecule drugs to protein biologics and the associated challenges, particularly the immunogenic response.

Review the EU Medical Device Regulation (MDR) changes, specifically with respect to integral combination products, and examine the technical documentation packages supporting functionality and content.

Roger Cone, Ph.D., Founder and Chair of the Scientific Advisory Board at Courage Therapeutics, talks about discovering obesity-related protein receptors in the brain, the need for obesity treatments with fewer side effects than currently available GLP-1 therapies, and the value of pairing scientific leadership with a strong business partner as CEO.

In this episode of "Better Biopharma," Abalone Bio's CEO and co-founder, Richard Yu, Ph.D., explains how the company's functional antibody selection technology (FAST) platform differs from traditional affinity screening.

There’s no need to deal with complex empirical calibration models, reagents, or unreliable auto-sampling systems to implement in-line bioreactor monitoring.

Explore how advanced cell line development and upstream processing strategies optimize both productivity and therapeutic effectiveness, ensuring the development of high-quality biologics.